Centessa Pharmaceuticals plc (CNTA)

8.87 -0.08 (-0.89%) 收市：04:00PM EDT

Centessa Pharmaceuticals plc

1 Ashley Road
3rd Floor
Altrincham WA14 2DT
United Kingdom

https://www.centessa.com

版塊: Healthcare
行業: Biotechnology
全職員工: 76

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Saurabh Saha M.D., Ph.D.	CEO & Director	1.04M	無	1976
Dr. David M. Chao Ph.D.	Chief Administrative Officer	710.3k	無	1968
Dr. Antoine Yver M.D., M.Sc.	Executive VP & Chairman of Development	773.14k	無	1958
Dr. Gregory M. Weinhoff M.B.A., M.D.	Principal Accounting Officer & CFO	655k	無	1971
Ms. Tia L. Bush	Chief Technology & Quality Officer	無	無	1971
Ms. Kristen K. Sheppard Esq., J.D.	Senior Vice President of Investor Relations & Corporate Communications	無	無	無
Mr. Iqbal J. Hussain L.L.B.	General Counsel, Chief Compliance Officer & Corporate Secretary	無	無	1981
Ms. Karen M. Anderson	Chief People Officer	無	無	1968
Dr. Harris L. Rotman Ph.D.	Senior Vice President of Regulatory Affairs	無	無	無
Dr. Patrick Yue M.D.	Senior VP of Clinical Development & Innovative Medicines	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

公司管治

截至 無 止，Centessa Pharmaceuticals plc 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。